1. Home
  2. PCB vs AKBA Comparison

PCB vs AKBA Comparison

Compare PCB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCB Bancorp

PCB

PCB Bancorp

HOLD

Current Price

$25.35

Market Cap

351.0M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.93

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCB
AKBA
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
351.0M
375.0M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
PCB
AKBA
Price
$25.35
$0.93
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$25.50
$4.67
AVG Volume (30 Days)
19.8K
5.5M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
3.65%
N/A
EPS Growth
48.28
93.94
EPS
0.74
N/A
Revenue
$2,899,000.00
N/A
Revenue This Year
$13.73
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$33.55
N/A
Revenue Growth
4.51
N/A
52 Week Low
$19.29
$0.88
52 Week High
$25.15
$4.08

Technical Indicators

Market Signals
Indicator
PCB
AKBA
Relative Strength Index (RSI) 60.44 33.94
Support Level $21.12 $0.88
Resistance Level N/A $1.56
Average True Range (ATR) 0.45 0.07
MACD 0.02 0.00
Stochastic Oscillator 83.06 27.29

Price Performance

Historical Comparison
PCB
AKBA

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: